New drug duo tested for Tough-to-Treat blood cancer
NCT ID NCT05083208
Summary
This early-stage study tested the safety and best dose of a two-drug combination (parsaclisib and chidamide) for adults with peripheral T-cell lymphoma that has come back or not responded to prior treatments. The main goals were to see how well patients tolerated the drugs and to find the safest dose for future testing. The study was terminated and involved a small group of 12 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.